<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312467668</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312467668</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lupus nephritis and non-Hodgkin lymphoma simultaneously diagnosed in a patient on methimazole</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lionaki</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467668">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312467668"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Vlachopanos</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467668">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Georgalis</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467668">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ziakas</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312467668">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gakiopoulou</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312467668">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Petra</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467668">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boletis</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467668">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312467668"><label>1</label>Nephrology and Transplantation Department, Laiko Hospital, Greece</aff>
<aff id="aff2-0961203312467668"><label>2</label>University of Athens, Greece</aff>
<author-notes>
<corresp id="corresp1-0961203312467668">Correspondence to: Sophia Lionaki, Nephrology and Transplantation Department, Laiko Hospital, AG Thoma 17, Athens 11527, Greece. Email: <email>sofia.lionaki@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>98</lpage>
<history>
<date date-type="received"><day>20</day><month>3</month><year>2011</year></date>
<date date-type="accepted"><day>18</day><month>10</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>A 78 year old white male on methimazole due to Grave’s thyroiditis presented with acute renal failure after a short term history of progressive shortness of breath, malaise, myalgias, arthralgias, and bilateral lower limb swelling. The abdomen was remarkable for splenomegaly and lower extremities for erythema nodosum. No peripheral lymphadenopathy was detected. Serum albumin was 1.7 g/dl and very high erythrocyte sedimentation rate. Urine sediment was very active with dysmorphic red blood cells and casts and significant proteinuria (6.6 grams/day). Serum complements were abnormally low and antinuclear and anti-DNA antibodies were positive. Renal histopathology revealed membranoproliferative glomerulonephritis, along with a full house pattern on IFF consistent with lupus nephritis. Bone marrow aspiration revealed a 40% infiltration by a lymphocyte population of small cells consistent with a B cell non-Hodgkin lymphoma.</p>
<p>The patient was treated with methylprednisolone, cyclophosphamide and rituximab and acute dialysis. Over the following weeks the patient became dialysis independent and returned to his baseline GFR.</p>
</abstract>
<kwd-group>
<kwd>Acute lupus</kwd>
<kwd>glomerulonephritis</kwd>
<kwd>lymphoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312467668" sec-type="intro"><title>Introduction</title>
<p>Infrequent combinations of immunological disorders in the same individual often contribute to the unraveling of interesting implications regarding the pathogenesis of glomerular diseases, allowing us to postulate novel hypotheses. Drug-induced lupus is a well-known clinical entity,<sup><xref ref-type="bibr" rid="bibr1-0961203312467668">1</xref></sup> indistinguishable from idiopathic disease, which can be induced by more than 40 medications, underlying the interplay between environmental exposures and the host. There is no apparent common chemical structure or pharmacologic property among the various medications that trigger the clinical phenotype of lupus, and all potential signs and symptoms can be observed. Yet, glomerulonephritis is a rare complication of hematological malignancies,<sup><xref ref-type="bibr" rid="bibr2-0961203312467668">2</xref>–<xref ref-type="bibr" rid="bibr4-0961203312467668">4</xref></sup> and non-Hodgkin lymphomas (NHLs) have commonly been associated with glomerular diseases<sup><xref ref-type="bibr" rid="bibr4-0961203312467668">4</xref></sup> and especially with a membranoproliferative histological pattern.<sup><xref ref-type="bibr" rid="bibr5-0961203312467668">5</xref></sup> On the other hand, lymphomas in the setting of lupus are relatively well known, and typically are found late during the course of the disease.<sup><xref ref-type="bibr" rid="bibr6-0961203312467668">6</xref></sup> This report describes a patient on therapy with methimazole who presented with lupus-like syndrome, including generalized symptoms and severe glomerulonephritis in association with NHL. Appropriate treatment led to a significant response in both clinical entities.</p>
</sec>
<sec id="sec2-0961203312467668" sec-type="cases"><title>Case report</title>
<p>A 78-year-old white male with a history of Graves’ disease currently on methimazole presented with an eight-week history of progressive shortness of breath, malaise, myalgias, arthralgias, bilateral lower limb swelling and a 5-kilogram weight gain. He also reported reddish colored urine during the same period with no history of trauma. His past medical history was significant for hypertension and hyperthyroidism due to Graves’ thyroiditis. He was on a thiazidic diuretic for consecutive years and methimazole for almost two years.</p>
<p>On physical examination, temperature was 37.2°C, pulse was 78 beats per minute and blood pressure was 160/95 mmHg. Jugular veins were distended and heart sounds were normal. Breath sounds were decreased on the left side of the chest. The abdomen was remarkable for splenomegaly. There was marked pretibial edema while lower extremities were also significant for erythema nodosum. No peripheral lymphadenopathy was detected.
<fig id="fig1-0961203312467668" position="float"><label>Figure 1</label><caption><p>Erythema nodusum (225 × 169 mm) (72 × 72 dots per inch).</p></caption><graphic xlink:href="10.1177_0961203312467668-fig1.tif"/>
</fig></p>
<p>Initial laboratory evaluation showed a white blood cell count of 3.7 × 10<sup>9</sup>/l, hematocrit 25%, and platelet count 175,000/µl. Serum creatinine was 5.3 mg/dl, and urea 147 mg/dl. Serum electrolytes, hepatic transaminases, alkaline phosphatase, and international normalized ratio (INR) were normal. Serum albumin was 1.7 g/dl and erythrocyte sedimentation rate was 130 mm in the first hour. Urinalysis showed 3 + blood, 3 + protein, with red blood cells (RBCs) casts and occasional granular casts. Twenty-four-hour protein excretion was 6.6 gr (mean of two serial measurements). Serum immunofixation electrophoresis, serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) were negative for monoclonal bands. Serum complement (C3) was 37.8 mg/dl (75–140), C4 was 3.7 mg/dl (10–34). Rheumatoid factor was 23.5 IU/ml (&lt;20). Antinuclear antibodies (ANAs) were positive (1/640) and anti-DNA antibodies were 9.6 IU/ml (0–7). Cryoglobulins and antineutrophil cytoplasmic antibody (ANCA) tests were negative. Tests for hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus were negative. Thyroid-stimulating hormone (TSH): 1.72 mU/l (0.3–4), T3: 1.2 nmol/l (1.23–3.08), T4: 59.4  nmol/l (58–154). Chest X-ray showed a left pleural effusion and a normal-sized heart. Computerized tomography of the abdomen revealed hepatosplenomegaly and periaortic lymphadenopathy. Doppler sonography of the kidneys showed no abnormality.</p>
<sec id="sec3-0961203312467668"><title>Histopathology findings</title>
<p>A percutaneous renal biopsy was performed. Light microscopy showed increased cellularity in all glomeruli and marked subendothelial deposits. Silver staining showed double contours within the capillary loops. There was one cellular and one fibrocellular crescent in a specimen of 16 glomeruli in total. Immunofluorescence (IFF) studies showed granular staining for IgG, IgM, IgA, C3, C4, and C1q. These histologic findings were consistent with membranoproliferative glomerulonephritis, along with a full house pattern on IFF consistent with lupus nephritis, Class IVG, by International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2004. There was no histological evidence of cryoglobulin deposition or amyloidosis or lymphomatous infiltration. Bone marrow aspiration revealed 35–40% infiltration by a lymphocyte population of small cells. Immunophenotyping showed clonality with expression of CD5(+), CD20(+), CD23(+) and CD38(+) cells, consistent with a B cell non-Hodgkin lymphoma.
<fig id="fig2-0961203312467668" position="float"><label>Figure 2</label><caption><p>Circumferential crescent with segmental rupture of the Bowman’s capsule (<italic>periodic acid-Schiff (</italic>PAS) × 400). (262 × 211 mm) (72 × 72 dots per inch).</p></caption><graphic xlink:href="10.1177_0961203312467668-fig2.tif"/>
</fig>
<fig id="fig3-0961203312467668" position="float"><label>Figure 3</label><caption><p>IgG immunohistochemical staining showing intense peripheral subendothelial deposits (176 × 124 mm) (72 × 72 dots per inch).</p></caption><graphic xlink:href="10.1177_0961203312467668-fig3.tif"/>
</fig></p>
</sec>
<sec id="sec4-0961203312467668"><title>Treatment and follow-up</title>
<p>The patient was treated with methylprednisolone 500 mg/day for three consecutive days, with gradual tapering afterwards, plus cyclophosphamide 0.5–0.75 g/m<sup>2</sup> body surface area (BSA) by month, and four weekly courses of rituximab, 375 mg/m<sup>2</sup> BSA each. Renal replacement therapy was required during the first two weeks of hospitalization, when glomerular filtration rate (GFR) was severely deteriorated. Methimazole was discontinued and no other medication was added as the patient was found to be euthyroid. Over the following weeks renal function was significantly improved, the patient became dialysis independent and returned to his baseline estimated glomerular filtration rate (eGFR) (34 ml/min/1.73 m2). Three months later, microscopic hematuria was resolved and 24-hour protein excretion was decreased to 600 mg/day. No further immunosuppressive therapy was given for the lupus syndrome as the patient entered remission soon after the discontinuation of the offending drug.</p>
</sec>
</sec>
<sec id="sec5-0961203312467668" sec-type="discussion"><title>Discussion</title>
<p>Systemic lupus erythematosus (SLE), as well as Graves’ disease, typically affect young women, whereas its occurrence in elderly males is particularly rare. Among individuals older than 55 years, incidence rate is less than 15%, while the female to male ratio is approximately 8:1.<sup><xref ref-type="bibr" rid="bibr7-0961203312467668">7</xref></sup> However, lupus-like syndromes can occasionally be induced by certain drugs<sup><xref ref-type="bibr" rid="bibr8-0961203312467668">8</xref></sup> at any age. Among others, antithyroid agents have long been associated with the development of rheumatic manifestations including lupus, serum sickness and vasculitis.<sup><xref ref-type="bibr" rid="bibr9-0961203312467668">9</xref></sup> Several reports in the literature associate the development of overt clinically dissimilar lupus syndromes in patients treated with methimazole,<sup><xref ref-type="bibr" rid="bibr10-0961203312467668">10</xref>–<xref ref-type="bibr" rid="bibr14-0961203312467668">14</xref></sup> and a positive correlation between ANAs and antibodies against anti-dsDNA (anti-dsDNA Abs) has been shown to exist in those patients.<sup><xref ref-type="bibr" rid="bibr15-0961203312467668">15</xref></sup> Renal involvement with characteristics of lupus nephritis following exposure to antithyroid agents is infrequent,<sup><xref ref-type="bibr" rid="bibr10-0961203312467668">10</xref>,<xref ref-type="bibr" rid="bibr16-0961203312467668">16</xref></sup> reported in 17% of cases, in sharp contrast with idiopathic SLE.<sup><xref ref-type="bibr" rid="bibr17-0961203312467668">17</xref></sup> It has been postulated that antithyroid agents may carry immunologic effects, including granulocytopenia<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup> (defined as granulocytes less than 0.25 × 10<sup>9</sup>/l) in less than 0.3% of treated patients. In some cases this idiosyncratic reaction has been associated with the identification of anti-neutrophil autoantibodies.<sup><xref ref-type="bibr" rid="bibr19-0961203312467668">19</xref></sup> Various physiologic pathways have been implicated in the pathogenesis of lupus syndrome with the thioureylene derivatives; one of them involves accumulation of the drug within neutrophils, binding to myeloperoxidase and modification of its configuration, leading to the uncontrolled production of autoantibodies, a hallmark of SLE. The aberrant immune responses described in patients receiving such therapy may also be related to the underlying abnormal immunologic function of patients with Graves’ disease.<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup> The mechanism by which the drug stimulates the immunological response may involve the thiol group, which permits covalent bonding to macromolecules. Such a complex with thyroglobulin has been demonstrated. The drug may therefore serve as a hapten and induce antibody production. This mechanism may give rise to single auto antibodies including insulin, glucagon, neutrophils, and marrow precursor cells. When multiple auto-antigens are targeted in a given patient, drug modification of multiple macromolecules may be involved.<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup> Alternatively, metabolites of the medication may compete with certain groups as a substrate and therefore inhibit the synthesis of DNA.<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup> If the metabolite is incorporated into DNA, abnormalities of regulation of immune function may occur that ultimately result in the expression of adverse effects.<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup> Genetic deficiency of metabolizing enzymes may also be present in such cases.<sup><xref ref-type="bibr" rid="bibr18-0961203312467668">18</xref></sup></p>
<p>On the other hand, development of lymphoma among patients with SLE is not rare, especially non-Hodgkin diffuse large B cell lymphomas.<sup><xref ref-type="bibr" rid="bibr20-0961203312467668">20</xref></sup> The concurrent diagnosis of lupus-like syndrome and NHL in our patient might represent a disorder of the immune system and the function of B cell specifically. We certainly cannot identify the precise mechanism or time of onset of each clinical incident in this case. However, the sequence of signs and symptoms related to lupus and glomerulonephritis dominated the clinical picture at first glance. Glomerulonephritis is indeed a rare complication of lymphoma, most commonly described in association with Hodgkin disease and minimal change nephropathy.<sup><xref ref-type="bibr" rid="bibr2-0961203312467668">2</xref></sup> There are relatively few reports of glomerulonephritis in patients with NHL, both T and B cell lymphomas, and there is an increased incidence of membranoproliferative glomerulonephritis in this group of patients.<sup><xref ref-type="bibr" rid="bibr21-0961203312467668">21</xref></sup> A circulating factor produced by lymphocytes altering the glomerular permeability or a setting of cryoglobulinemia have been implicated.<sup><xref ref-type="bibr" rid="bibr21-0961203312467668">21</xref></sup> Also, certain medicines have been shown to impair chief mechanisms that contribute to B cell tolerance to self.<sup><xref ref-type="bibr" rid="bibr22-0961203312467668">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312467668">23</xref></sup> Related to this, it has been suggested that drugs may represent epigenetic factors playing a role in triggering disease onset in predisposed individuals.<sup><xref ref-type="bibr" rid="bibr23-0961203312467668">23</xref></sup> Employment of rituximab in the treatment of lupus nephritis has been shown efficacious,<sup><xref ref-type="bibr" rid="bibr24-0961203312467668">24</xref></sup> and disease remission has been associated with reduced T cell expression of the CD40 ligand, CD69, and human leukocyte antigen-DR (HLA-DR).<sup><xref ref-type="bibr" rid="bibr25-0961203312467668">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203312467668">26</xref></sup></p>
<p>In this report, a patient was diagnosed with lupus-like syndrome and NHL at the same clinical presentation, pointing to an interesting interplay between rheumatic disorders and malignancies. Defects of specific pathways of the immune system, acquired as age evolves and/or environmental exposures grow, may be the missing link in the pathogenesis of such phenomena.</p>
</sec>
</body>
<back>
<sec id="sec6-0961203312467668"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec7-0961203312467668"><title>Conflict of interest</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312467668"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>D’Agati</surname><given-names>VD</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Jennette</surname><given-names>JC</given-names></name><name><surname>Olson</surname><given-names>JL</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Renal disease in systemic lupus erythematosus</article-title>. <source>Heptinstall's pathology of the kidney</source>, <edition>6th ed</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott, Williams &amp; Wilkins</publisher-name>, <year>2007</year>. p. <fpage>567</fpage>–<lpage>568</lpage>.</citation></ref>
<ref id="bibr2-0961203312467668"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moulin</surname><given-names>B</given-names></name><name><surname>Ronco</surname><given-names>PM</given-names></name><name><surname>Mougenot</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas</article-title>. <source>Kidney Int</source> <year>1992</year>; <volume>42</volume>: <fpage>127</fpage>–<lpage>135</lpage>.</citation></ref>
<ref id="bibr3-0961203312467668"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da'as</surname><given-names>N</given-names></name><name><surname>Polliack</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: A retrospective study in 700 patients</article-title>. <source>Eur J Haematol</source> <year>2001</year>; <volume>67</volume>: <fpage>158</fpage>–<lpage>164</lpage>.</citation></ref>
<ref id="bibr4-0961203312467668"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>L</given-names></name><name><surname>Adu</surname><given-names>D</given-names></name></person-group>. <article-title>Glomerulonephritis and non-Hodgkin lymphoma</article-title>. <source>Nephrol Dial Transplant</source> <year>1997</year>; <volume>12</volume>: <fpage>1520</fpage>–<lpage>1525</lpage>.</citation></ref>
<ref id="bibr5-0961203312467668"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gayed</surname><given-names>M</given-names></name><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Ramsey-Goldman</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Lupus and cancer</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>479</fpage>–<lpage>485</lpage>.</citation></ref>
<ref id="bibr6-0961203312467668"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Voulgarelis</surname><given-names>M</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group>. <article-title>The risk of lymphoma development in autoimmune diseases: A meta-analysis</article-title>. <source>Arch Intern Med</source> <year>2005</year>; <volume>165</volume>: <fpage>2337</fpage>–<lpage>2344</lpage>.</citation></ref>
<ref id="bibr7-0961203312467668"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazari</surname><given-names>L</given-names></name><name><surname>Ouarzane</surname><given-names>M</given-names></name><name><surname>Zouali</surname><given-names>M</given-names></name></person-group>. <article-title>Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2007</year>; <volume>104</volume>: <fpage>6317</fpage>–<lpage>6322</lpage>.</citation></ref>
<ref id="bibr8-0961203312467668"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>ten Holder</surname><given-names>S</given-names></name><name><surname>Joy</surname><given-names>MS</given-names></name><name><surname>Falk</surname><given-names>RJ</given-names></name></person-group>. <article-title>Cutaneous and systemic manifestations of drug-induced vasculitis</article-title>. <source>Ann Pharmacother</source> <year>2002</year>; <volume>36</volume>: <fpage>130</fpage>–<lpage>147</lpage>.</citation></ref>
<ref id="bibr9-0961203312467668"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ballou</surname><given-names>SP</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group>. <article-title>Clinical features of systemic lupus erythematosus: Differences related to race and age of onset</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>55</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr10-0961203312467668"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Tsai</surname><given-names>WY</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><etal/></person-group>. <article-title>Methimazole-induced lupus erythematosus: A case report</article-title>. <source>J Microbiol Immunol Infect</source> <year>2003</year>; <volume>36</volume>: <fpage>278</fpage>–<lpage>281</lpage>.</citation></ref>
<ref id="bibr11-0961203312467668"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thong</surname><given-names>HY</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Chiu</surname><given-names>HC</given-names></name></person-group>. <article-title>Methimazole-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus-like syndrome with a cutaneous feature of vesiculo-bullous systemic lupus erythematosus</article-title>. <source>Acta Derm Venereol</source> <year>2002</year>; <volume>82</volume>: <fpage>206</fpage>–<lpage>208</lpage>.</citation></ref>
<ref id="bibr12-0961203312467668"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato-Matsumura</surname><given-names>KC</given-names></name><name><surname>Koizumi</surname><given-names>H</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil</article-title>. <source>J Dermatol</source> <year>1994</year>; <volume>21</volume>: <fpage>501</fpage>–<lpage>507</lpage>.</citation></ref>
<ref id="bibr13-0961203312467668"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Two cases of systemic lupus erythematosus associated with hyperthyroidism</article-title>. <source>Jpn J Med</source> <year>1987</year>; <volume>26</volume>: <fpage>373</fpage>–<lpage>376</lpage>.</citation></ref>
<ref id="bibr14-0961203312467668"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takuwa</surname><given-names>N</given-names></name><name><surname>Kojima</surname><given-names>I</given-names></name><name><surname>Ogata</surname><given-names>E</given-names></name></person-group>. <article-title>Lupus-like syndrome — a rare complication in thionamide treatment for Graves' disease</article-title>. <source>Endocrinol Jpn</source> <year>1981</year>; <volume>28</volume>: <fpage>663</fpage>–<lpage>667</lpage>.</citation></ref>
<ref id="bibr15-0961203312467668"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CN</given-names></name><name><surname>Hsu</surname><given-names>TC</given-names></name><name><surname>Chou</surname><given-names>HH</given-names></name><etal/></person-group>. <article-title>Anti-nuclear antibody, anti-DNA, and aCL in Graves' disease patients treated with propyluracil or methimazole</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>450</fpage>–<lpage>454</lpage>.</citation></ref>
<ref id="bibr16-0961203312467668"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chávez-Legaspi</surname><given-names>M</given-names></name><name><surname>Ocampo-Campos</surname><given-names>R</given-names></name><name><surname>García-Velarde</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Rheumatic features of Grave's disease in children [in Spanish]</article-title>. <source>Gac Med Mex</source> <year>1992</year>; <volume>128</volume>: <fpage>35</fpage>–<lpage>39</lpage>.</citation></ref>
<ref id="bibr17-0961203312467668"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>GV</given-names></name><name><surname>Bastacky</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>JP</given-names></name></person-group>. <article-title>Propylthiouracil-induced diffuseproliferative lupus nephritis: Review of immunological complications</article-title>. <source>J Am Soc Nephrol</source> <year>1997</year>; <volume>8</volume>: <fpage>1205</fpage>–<lpage>1210</lpage>.</citation></ref>
<ref id="bibr18-0961203312467668"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>SS</given-names></name><name><surname>Fantus</surname><given-names>IG</given-names></name></person-group>. <article-title>Adverse immunologic effects of antithyroid drugs</article-title>. <source>CMAJ</source> <year>1987</year>; <volume>136</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr19-0961203312467668"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berkman</surname><given-names>EM</given-names></name><name><surname>Orlin</surname><given-names>JB</given-names></name><name><surname>Wolfsdorf</surname><given-names>J</given-names></name></person-group>. <article-title>An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome</article-title>. <source>Transfusion</source> <year>1983</year>; <volume>23</volume>: <fpage>135</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr20-0961203312467668"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woosley</surname><given-names>RL</given-names></name><name><surname>Drayer</surname><given-names>DE</given-names></name><name><surname>Reidenberg</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome</article-title>. <source>N Engl J Med</source> <year>1978</year>; <volume>298</volume>: <fpage>1157</fpage>–<lpage>1159</lpage>.</citation></ref>
<ref id="bibr21-0961203312467668"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SL</given-names></name><name><surname>CHase</surname><given-names>PH</given-names></name></person-group>. <article-title>Drug-induced systemic lupus erythematosus: A critical review</article-title>. <source>Semin Arthritis Rheum</source> <year>1975</year>; <volume>5</volume>: <fpage>83</fpage>–<lpage>103</lpage>.</citation></ref>
<ref id="bibr22-0961203312467668"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almroth</surname><given-names>G</given-names></name><name><surname>Eneström</surname><given-names>S</given-names></name><name><surname>Hed</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Autoantibodies to leucocyte antigens in hydralazine-associated nephritis</article-title>. <source>J Intern Med</source> <year>1992</year>; <volume>231</volume>: <fpage>37</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr23-0961203312467668"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornacchia</surname><given-names>E</given-names></name><name><surname>Golbus</surname><given-names>J</given-names></name><name><surname>Maybaum</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity</article-title>. <source>J Immunol</source> <year>1988</year>; <volume>140</volume>: <fpage>2197</fpage>–<lpage>2200</lpage>.</citation></ref>
<ref id="bibr24-0961203312467668"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Khursigara</surname><given-names>G</given-names></name><name><surname>Rubin</surname><given-names>RL</given-names></name></person-group>. <article-title>Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils</article-title>. <source>Science</source> <year>1994</year>; <volume>266</volume>: <fpage>810</fpage>–<lpage>813</lpage>.</citation></ref>
<ref id="bibr25-0961203312467668"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellemkjaer</surname><given-names>L</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Engels</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>657</fpage>–<lpage>666</lpage>.</citation></ref>
<ref id="bibr26-0961203312467668"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sfikakis</surname><given-names>PP</given-names></name><name><surname>Boletis</surname><given-names>JN</given-names></name><name><surname>Lionaki</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial</article-title>. <source>Arthritis Rheum</source> <year>2005</year>; <volume>52</volume>: <fpage>501</fpage>–<lpage>513</lpage>.</citation></ref>
</ref-list>
</back>
</article>